Research On The Effect Of Ginsenoside Rb2 On Colorectal Cancer Cells By Regulating The TGF-β/smad Signaling Pathway

Objective:To explore whether Ginsenoside Rb2 is cytotoxic to CRC cells HCT116 and SW620,and whether it can inhibit them by regulating the TGF-β/smad signaling pathway,so as to further explore whether Ginsenoside Rb2 can be a future treatment for CRC Potential drugs.Methods:1.CRC cells HCT116 and SW620 and human normal intestinal epithelial cells NCM460 were used as research cells,and each group of cells was divided into blank group(no treatment),TGF-β1 inhibitor LY364947 group(1μM),Ginsenoside Rb2 low-dose group(0.1μg/ml),Ginsenoside Rb2 medium-dose group(1μg/ml),Ginsenoside Rb2 high-dose group(10μg/ml)for 24h,48h and 72h intervention treatment,the treated cells were measured by CCK-8 method for cell viability.2.①The CRC cells HCT116 were divided into blank group(no treatment),Ginsenoside Rb2 low-dose group(0.1μg/ml),Ginsenoside Rb2 medium-dose group(1μg/ml),and Ginsenoside Rb2 high-dose group(10μg/ml).ml)for intervention treatment,and the processed cells are used to measure the protein expression of TGF-β1,TGFβRI and TGFβRII by immunoblotting.②The CRC cells HCT116 were divided into blank group(no treatment),Ginsenoside Rb2 low-dose group(0.1 μg/ml),Ginsenoside Rb2 medium-dose group(1μg/ml),Ginsenoside Rb2 high-dose group(10μg/ml)Intervention treatment was carried out,and the processed cells were used to determine the expression of smad2/3,p-smad2/3,and smad4 protein by immunoblotting.3.①Divide CRC cell SW620 into blank group(no treatment),Ginsenoside Rb2 low-dose group(0.1μg/ml),Ginsenoside Rb2 medium-dose group(1μg/ml),Ginsenoside Rb2 high-dose group(10μg/ml),respectively.ml)for intervention treatment,and the processed cells are used to measure the protein expression of TGF-β1,TGFβRI and TGFβRII by immunoblotting.②The CRC cells SW620 were divided into blank group(no treatment),Ginsenoside Rb2 low-dose group(0.1μg/ml),Ginsenoside Rb2 medium-dose group(1μg/ml),and Ginsenoside Rb2 high-dose group(10μg/ml).Intervention treatment was carried out,and the processed cells were used to determine the expression of smad2/3,p-smad2/3,and smad4 protein by immunoblotting.Results:1.Compared with the control group without any treatment,Ginsenoside Rb2 has a significant inhibitory effect on the cell viability of HCT116 cells and SW620 cells,and is dose-dependent within a certain range(P<0.05);Ginsenoside Rb2 is The cell viability of human normal intestinal epithelial cells NCM460 cells has no obvious inhibitory effect(P>0.05).2.①Compared with the control group without any treatment,Ginsenoside Rb2 has a significant inhibitory effect on the protein expression of TGF-β1,TGFβRI and TGFβRII in HCT116 cells(P<0.05);②Compared with the control group without any treatment In the control group,Ginsenoside Rb2 has a significant inhibitory effect on the protein expression of P-smad2/3 and smad4 in HCT116 cells(P<0.05),but has no significant inhibitory effect on the protein expression of smad2/3(P>0.05).3.①Compared with the control group without any treatment,Ginsenoside Rb2 has a significant inhibitory effect on the protein expression of TGF-β1,TGFβRI and TGFβRII in SW620 cells(P<0.05);②Compared with the control group without any treatment In the control group,Ginsenoside Rb2 had a significant inhibitory effect on the protein expression of P-smad2/3 and smad4 in SW620 cells(P<0.05),but had no significant inhibitory effect on the protein expression of smad2/3(P>0.05).Conclusion:Ginsenoside Rb2 has obvious cytotoxicity to CRC cells HCT116 and SW620,and can inhibit CRC cells by regulating the TGF-β/smad signaling pathway,thereby playing a therapeutic effect on CRC.Ginsenoside Rb2 may be used as a potential alternative drug for the treatment of CRC.